Asthma
Conditions
Keywords
Acute Asthma exacerbation
Brief summary
This is a study of levalbuterol tartrate HFA inhalation aerosol MDI in pediatric subjects birth to ≤ 48 months of age who go to the Emergency Department (ED) or their physician's office with an acute bronchospasm. Subjects presenting to the ED or physician's office with an acute bronchospasm must have a history of reactive airways disease, based on subjects' parent/guardian report.
Detailed description
This is a study to determine the safety and tolerability of cumulative dosing with levalbuterol tartrate HFA inhalation aerosol MDI using a valved holding chamber and facemask in pediatric subjects birth to ≤ 48 months of age with acute bronchospasm. It is a randomized, double-blind, parallel-group, multicenter, trial of 3 doses of levalbuterol tartrate HFA inhalation aerosol MDI in pediatric subjects birth to ≤ 48 months of age who present to either the Emergency Department (ED) or their physician's office with an acute bronchospasm. Subjects presenting to the ED or physician's office with an acute bronchospasm must have a history of reactive airways disease, based on subjects' parent/guardian report. Eligible subjects whose parent(s) or legal guardian(s) provide written informed consent to participate will be randomized to 1 of 2 treatments. Treatment 1 consists of 3 doses, with each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA \[cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol\]); Treatment 2 consists of 3 doses, with each dose comprised of 8 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff \[cumulative dose of 1080 mcg of levalbuterol tartrate HFA inhalation aerosol\]). For each Treatment, study medication will be administered every 20 minutes over a period of 1 hour for three doses.
Interventions
DRUGlevalbuterol tartrate HFA inhalation aerosol
DRUGplacebo
Sponsors
Sumitomo Pharma America, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
No minimum to 48 Months
Healthy volunteers
No
Inclusion criteria
1. Male or female from birth to 48 months of age, inclusive, whose parent(s) or legal guardian(s) provide written informed consent prior to study participation and are willing to comply with study procedures. 2. Subject experiencing acute bronchospasm requiring a bronchodilator and who have a history of wheezing.
Exclusion criteria
1. Subject with a severe illness that, in the opinion of the Investigator, could jeopardize subject safety. 2. Subject received ≥ 8 puffs (MDI) of a beta-2 agonist or 2.5 mg of nebulized levalbuterol, or albuterol 5.0 mg within 4 hours prior to ED or physician's office admittance. 3. Subject received ipratropium within 4 hours prior to ED or physician's office admittance. 4. Subject who participated in an investigational drug study within 30 days prior to enrollment, or who previously participated in the current study. 5. Subject with a known sensitivity to levalbuterol or racemic albuterol or any of the excipients contained in any of these formulations. 6. Subject using any prescription drug (including beta-blockers) with which levalbuterol or racemic albuterol sulfate administration is contraindicated. 7. Subject with a history of clinically significant abnormalities that could interfere with the metabolism or excretion of the study medication (eg, renal, hepatic, metabolic, or endocrine abnormalities). 8. Subject with a history of cancer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Treatment-emergent Adverse Events. | Week 1 | Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided. |
| The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Serious Adverse Events. | Week 1 | Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided. |
| The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Treatment-emergent Adverse Events Leading to Discontinuation. | Week 1 | Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Pulmonary Score (Individual Component Scores) After Each Dose | 20 minutes, 40 minutes, 60 minutes | Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided. |
| Change From Baseline in Pulmonary Score (Total Score) to End of Treatment | Day 1 | Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided. |
| Number and Percentage of Subjects Determined to be Stabilized After Treatment | Day 1 | Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided. |
| Change From Baseline in Pulmonary Score (Individual Component Scores) to End of Treatment | Day 1 | Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided. |
| Change From Baseline in Pulmonary Score (Total Score) After Each Dose | 20 minutes, 40 minutes, 60 minutes | Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol
levalbuterol tartrate HFA inhalation aerosol
placebo | 9 |
| Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.
levalbuterol tartrate HFA inhalation aerosol | 9 |
| Total | 18 |
Baseline characteristics
| Characteristic | Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol | Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 9 Participants | 9 Participants | 18 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Continuous | 17.1 months STANDARD_DEVIATION 12.75 | 18.6 months STANDARD_DEVIATION 10.21 | 17.8 months STANDARD_DEVIATION 11.23 |
| Region of Enrollment United States | 9 participants | 9 participants | 18 participants |
| Sex: Female, Male Female | 5 Participants | 6 Participants | 11 Participants |
| Sex: Female, Male Male | 4 Participants | 3 Participants | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 2 / 9 | 2 / 9 |
| serious Total, serious adverse events | 0 / 9 | 0 / 9 |
Outcome results
Primary
The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Serious Adverse Events.
Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.
Time frame: Week 1
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA | The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Serious Adverse Events. | 0 Number of Serious Adverse Events |
| Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol | The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Serious Adverse Events. | 0 Number of Serious Adverse Events |
Primary
The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Treatment-emergent Adverse Events.
Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.
Time frame: Week 1
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA | The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Treatment-emergent Adverse Events. | 4 Number of Adverse Events |
| Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol | The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Treatment-emergent Adverse Events. | 6 Number of Adverse Events |
Primary
The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Treatment-emergent Adverse Events Leading to Discontinuation.
Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.
Time frame: Week 1
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA | The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Treatment-emergent Adverse Events Leading to Discontinuation. | 0 Number of Discontinuations |
| Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol | The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Treatment-emergent Adverse Events Leading to Discontinuation. | 0 Number of Discontinuations |
Secondary
Change From Baseline in Pulmonary Score (Individual Component Scores) After Each Dose
Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.
Time frame: 20 minutes, 40 minutes, 60 minutes
Secondary
Change From Baseline in Pulmonary Score (Individual Component Scores) to End of Treatment
Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.
Time frame: Day 1
Secondary
Change From Baseline in Pulmonary Score (Total Score) After Each Dose
Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.
Time frame: 20 minutes, 40 minutes, 60 minutes
Secondary
Change From Baseline in Pulmonary Score (Total Score) to End of Treatment
Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.
Time frame: Day 1
Secondary
Number and Percentage of Subjects Determined to be Stabilized After Treatment
Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.
Time frame: Day 1